Streetbeat News

Partnerships

AAL

DAL

UAL

American Airlines Group Inc's pilots union has reached an agreement in principle with the company's management on proposed enhancements to the Tentative Agreement. The deal includes an increase in the pilot contract offer by over a billion dollars, aligning it with a tentative agreement reached by competitor United Airlines Holdings Inc and its pilots. The revised agreement needs approval from the union's board and a ratification vote. The pay rate increases are contingent on United pilots ratifying their agreement.

Portfolio Pulse from Akanksha Bakshi

July 28, 2023 | 1:26 pm

KR

SMFL

Smart for Life, Inc. (NASDAQ:SMFL) has announced that its subsidiary Ceautamed Worldwide LLC has expanded its distribution with Vitacost.com, a subsidiary of The Kroger Co. (NYSE:KR). Vitacost.com will distribute the company's proprietary Greens First products on its online platform. The move is part of Smart for Life's strategy to accelerate its omnichannel sales distribution.

Portfolio Pulse from Happy Mohamed

July 28, 2023 | 1:15 pm

SYF

Synchrony Financial (SYF) has expanded its partnership with Roto-Rooter to provide financing for plumbing services. This move is expected to increase the accessibility of Roto-Rooter's services to a wider customer base.

Portfolio Pulse from Benzinga Newsdesk

July 28, 2023 | 1:01 pm

ADMP

Adamis Pharmaceuticals Corporation (ADMP) has committed to fund a research grant to the Leiden University Medical Center (LUMC) Anesthesia and Pain Research Unit. The funding will support the work of Albert Dahan, MD, PhD, an expert on opioid-induced respiratory depression. The collaboration aims to assess the efficacy of 5mg intramuscular ZIMHI versus 4mg of intranasal naloxone, which is comparable to NARCAN®. The CEO of Adamis believes that if ZIMHI demonstrates superiority in reversing fentanyl-induced respiratory depression, national health organizations will update their emergency protocols to include the use of ZIMHI.

Portfolio Pulse from Happy Mohamed

July 28, 2023 | 12:31 pm

LI

NIO

XPEV

Chinese electric vehicle (EV) companies Nio, XPeng, and Li Auto are seeing their stocks rise, driven by the Chinese government's economic support and partnerships with Volkswagen and potentially Mercedes-Benz. Morgan Stanley analyst Tim Hsiao has raised the price targets for these companies, citing anticipated improvements in fundamentals in the second half.

Portfolio Pulse from Shanthi Rexaline

July 28, 2023 | 12:11 pm

ARBE

Arbe, a leading provider of next-generation 4D Imaging Radar Solutions, has received a preliminary order of $11.6M for radar chipsets and a $1M order for professional services from Weifu High Technology Group, a leading Chinese Tier 1 supplier. The orders are intended to meet Weifu's sales projections for 2024.

Portfolio Pulse from Benzinga Newsdesk

July 28, 2023 | 12:04 pm

BABA

META

TCEHY

Alibaba Group Holding Limited (NYSE:BABA) stock is trading higher amid a positive week that included a collaboration with Meta Platforms Inc (NASDAQ:META) and Ant Group on artificial intelligence, and a focus on its initial public offering. Alibaba also collaborated with Tencent Holdings Ltd (OTC: TCEHY) to promote their flagship brands, focusing on online shopping and esports. However, Alibaba's China commerce business has suffered from weak retail sales nationwide, with revenue falling by 3% year-on-year in the March quarter.

Portfolio Pulse from Anusuya Lahiri

July 28, 2023 | 11:37 am

TEF

VOD

Telefonica has reportedly approached Vodafone for a potential broadband deal in Spain, according to Bloomberg. No further details about the deal have been disclosed.

Portfolio Pulse from Charles Gross

July 28, 2023 | 11:22 am

AZN

IONS

Ionis Pharmaceuticals has expanded its existing collaboration with AstraZeneca to include exclusive rights for AstraZeneca to commercialize Eplontersen in Latin America. The two companies will continue to jointly develop and commercialize Eplontersen in the U.S.

Portfolio Pulse from Benzinga Newsdesk

July 28, 2023 | 11:08 am

OKYO

OKYO Pharma has announced a new agreement with Tufts Medical Center to conduct a 40-patient open-label trial evaluating the efficacy and safety of OK-101 in patients with neuropathic corneal pain. The investigational new drug is planned to be filed in Q4 of 2023.

Portfolio Pulse from Benzinga Newsdesk

July 28, 2023 | 11:03 am